Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2021)

Posted by Matt Breese on Feb 19, 2021

Find me on:

According to our recent payer coverage analysis for type 2 Diabetes (GLP-1 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for type 2 Diabetes (GLP-1 and Combo) treatments shows that under the pharmacy benefit, almost 46% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Diabetes GLP1-1Q2021Data snapshot as of Q1 2021

Trends: Access to Novo Nordisk’s Rybelsus (semaglutide) — the first oral glucagon-like peptide-1 receptor agonist (GLP-1) to treat adults with type 2 diabetes — got a major boost in January 2020 when Novo said Express Scripts, part of Cigna Corp., would cover the agent.  

To read the full Reality Check on Type 2 Diabetes (GLP-1 and Combo) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing